Skip Navigation


  • Our Mission

    To actively accelerate innovations to benefit patients, society, and the Dana-Farber Cancer Institute. We team with investigators to identify new discoveries and generate alliances to move science from bench to clinic for maximum impact.

    Our Vision

    To spark and fuel a spirit of innovation across the organization by providing effective tools to continuously question, create, and imagine what else might be possible.

    Collaboration Opportunities

    In collaborating with Dana-Farber, your organization will have access to the Institute's specialized expertise, and to the unique array of core facilities needed to explore new areas of research. Learn more about Dana-Farber Centers that are interested in partnering with industry. Explore Dana-Farber's extensive Core Facilities. And discover more opportunities to collaborate.

  • BODFI statistics for 2019
  • In partnership with the Innovation Office, Dana-Farber makes publicly available a list of FDA-approved therapeutics and diagnostics in which the Institute has a financial interest.
    View the list

  • Technology News


    Dana-Farber Researchers Map the Degradable Kinome, Providing Chemical Leads for Over 200 Kinases

    In a new paper published in Cell, Dana-Farber investigators described chemo-proteomic approaches to identify kinases that are amenable to targeted protein degradation (TPD). Eric Fischer, PhD, and colleagues used a panel of cell lines expressing nearly 500 protein kinases, and treated them with a library of 89 unique kinase degraders, which collectively bind the majority of the kinome. Using mass spectrometry, they identified which kinases are chemically degraded, and identified nearly 200 highly-degradable kinases and documented their findings in a searchable online database for researchers ...

    Jennifer Guerriero

    Investigating PARP Inhibitor Resistance in BRCA1-Associated Triple Negative Breast Cancer

    Recent clinical trials on BRCA1-associated triple negative breast cancer (TNBC) have investigated pairing PARP inhibitor therapy with immunotherapy. However, response rates have only shown modest improvements. Led by Jennifer Guerriero, PhD, a team of DF/BWCC researchers investigated and reported in Nature Cancer what else in the tumor microenvironment is limiting the efficacy of this combination. Through multi-omics profiling, PARP inhibitors were shown to increase intratumoral macrophages and modulated the metabolic phenotype, driven by the sterol regulatory element-binding protein 1 (SREBF1, SREBP1) pathway ...


    Paralog Enzymes VPS4A and VPS4B in Cancers Link to Genetic Vulnerability

    Andrew Aguirre, MD, PhD, in collaboration with the Cancer Dependency Map (DepMap) project at Dana-Farber and the Broad Institute of MIT and Harvard, reports in Cell Reports a genetic dependency that could be present in more than 30% of all cancers. In this study led by co-first authors Brenton Paolella, PhD, and Jasper Neggers, PhD, of the Aguirre Lab, large-scale CRISPR-SpCas9 and RNA interference (RNAi) loss-of-function screening of more than 600 cancer cell lines was implemented to systematically define synthetic lethal vulnerabilities associated with genomic loss of established tumor suppression genes ... 

    Coming Soon: Our Quarterly Newsletter

    Stay current with Dana-Farber technology news, transactions, patents, publications, events, and more.